激素受体阳性的绝经后乳腺癌患者血清性激素水平与Ki67表达的关系

The relationship between serum sex hormone levels and Ki67 expression in postmenopausal hormone receptors positive breast cancer patients

目的探讨绝经后激素受体阳性的乳腺癌患者血清性激素水平与癌细胞增殖情况之间的关系。方法检测57例雌激素受体阳性的绝经后乳腺癌患者血清性激素6项水平、雌激素受体(ER)、孕激素受体(PR)及增殖细胞核抗原(Ki67)表达状态。将ER和PR阳性的患者根据Ki67的水平分为Ki67低表达组(≤14%)与高表达组(>14%),比较两组间血清激素6项水平的差异。结果在57例ER阳性的患者中,Ki67低表达组睾酮水平高于Ki67高表达组(P=0.01),其余5项两组间的差异无统计学意义(P>0.05)。在40例PR阳性的患者中,Ki67低表达组和高表达组激素6项水平的差异均无统计学意义(P>0.05)。泌乳素在ER阳性和PR阳性的ki67高表达组均较低表达组患者升高,但差异均无统计学意义(P=0.07,P=0.05)。结论在ER阳性的绝经后乳腺癌患者中,Ki67低表达患者的血清睾酮水平较高,睾酮可能有抑制乳腺癌细胞增殖的作用。乳腺癌细胞的增殖情况与血清雌二醇、孕酮水平无关,而可能与泌乳素水平相关。

Objective To investigate the relationship between the serum sex hormone levels and the status of cancer cell proliferation in postmenopausal hormone receptors positive breast cancer patients. Methods The serum sex hormone levels, status of estrogen receptor（ER）, progesterone receptor （PR） and Ki67 were detected in fifty-seven ER positive breast cancer patients. The ER and PR positive patients were divided into Ki67 low（≤ 14%） and high（〉14%） expression groups. The serum sex hormone levels were compared between the two groups. Results In ER positive patients, the serum testosterone levels in the Ki67 low expression group were higher than Ki67 high expression group（P=0.01）. In PR positive patients, there were no significant differences between Ki67 high expression group and low group. The serum PRL levels were higher in Ki67 high expression group than in Ki67 low group, no matter in ER or PR positive patients, but there was no significant difference （P=0.07, P=0.05） . Conclusion In ER positive postmenopausal breast cancer patients, low Ki67 expression group has higher serum testosterone levels, testosterone may suppress the proliferation of breast cancer cells. The status of the breast cancer proliferation is not correlated with the serum estradiol or progesterone levels, while it may be correlated with the serum prolactin levels.